Lupin yesterday announced the launch of the authorised generic version of Duexis (Ibuprofen and Famotidine) tablets, 800 mg/26.6 mg, of Horizon Medicines, a company statement notified.
According to the statement, Ibuprofen and Famotidine tablets, 800 mg/26.6 mg, are indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis, and to decrease the risk of developing upper gastrointestinal ulcers, which, in the clinical trials, was defined as a gastric and/or duodenal ulcer in patients who are taking ibuprofen for those indications.
Ibuprofen and Famotidine tablets (Duexis) had estimated annual sales of $765 million in the US (IQVIA MAT July 2021), added the statement.